Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency

Pituitary

Volumn 15, Issue 4, 2012, Pages 589-597

  González Duarte, Daniel ^a   Madrazo Atutxa, Ainara ^b   Soto Moreno, Alfonso ^b   Leal Cerro, Alfonso ^b  

^a Hospital Punta Europa de Algeciras   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Adult growth hormone deficiency; Endothelial dysfunction; Free radicals; Oxidative stress

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; GLUTATHIONE; GLUTATHIONE DISULFIDE; INTERLEUKIN 6; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ADULT DISEASE; ARTERY; ARTICLE; BLOOD VESSEL FUNCTION; CARDIOVASCULAR RISK; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; EX VIVO STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPITUITARISM; INFLAMMATION; MALE; MYOGRAPHY; OXIDATIVE STRESS; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; SUBCUTANEOUS RESISTANCE ARTERY; VASODILATATION; WAIST HIP RATIO;

ADULT; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; FREE RADICALS; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NITRIC OXIDE; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84870339432     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0374-4     Document Type: Article

References (23)

1. Ricart W, Fernandez-Real JM (2003) Impact of hormonal deficit and cardiovascular risk factors on life expectancy in hypopituitarism. Med Clin (Barc) 120(16): 630-637
2. Evans LM, Davies JS, Anderson RA, Ellis GR, Jackson SK, Lewis MJ, Frenneaux MP, Rees A, Scanlon MF (2000) The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 142(3): 254-262
3. Colao A, Di Somma C, Savanelli MC, De Leo M, Lombardi G (2006) Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 16(Suppl):S41-S48
4. Bollerslev J, Ueland T, Jorgensen AP, Fougner KJ, Wergeland R, Schreiner T, Burman P (2006) Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 154(4): 537-543
5. Colao A, Di Somma C, Spiezia S, Savastano S, Rota F, Savanelli MC, Lombardi G (2008) Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab 93(9): 3416-3424
6. Fukuda I, Hizuka N, Ishikawa Y, Itoh E, Yasumoto K, Murakami Y, Sata A, Tsukada J, Kurimoto M, Okubo Y, Takano K (2004) Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth Horm IGF Res 14(6): 449-454
7. Gomez JM, Sahun M, Vila R, Domenech P, Catalina P, Soler J, Badimon L (2007) Elevation of Eselectin concentrations may correlate with potential endothelial dysfunction in individuals with hypopituitarism during therapy with growth hormone. Curr Neurovasc Res 4(1): 55-62
8. Joaquin C, Aguilera E, Granada ML, Pastor MC, Salinas I, Alonso N, Sanmarti A (2008) Effects of GH treatment in GHdeficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol 158(4): 483-490
9. Osterziel KJ, Bode-Boger SM, Strohm O, Ellmer AE, Bit-Avragim N, Hanlein D, Ranke MB, Dietz R, Boger RH (2000) Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy. Cardiovasc Res 45(2): 447-453
10. Setola E, Monti LD, Lanzi R, Lucotti P, Losa M, Gatti E, Galluccio E, Oldani M, Fermo I, Giovannelli M, Bosi E, Piatti P (2008) Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism 57(12): 1685-1690
11. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN (1999) Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84(2): 453-457
12. McCallum RW, Sainsbury CA, Spiers A, Dominiczak AF, Petrie JR, Sattar N, Connell JM (2005) Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clin Endocrinol (Oxf) 62(4): 473-479
13. Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM (2009) Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab 94(4): 1111-1117
14. Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W, Savastano S, Salvatore M, Lombardi G (2004) The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab 89(12): 5998-6004
15. Colao A, Cerbone G, Pivonello R, Aimaretti G, Loche S, Di Somma C, Faggiano A, Corneli G, Ghigo E, Lombardi G (1999) The growth hormone (GH) response to the arginine plus GHreleasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. J Clin Endocrinol Metab 84(4): 1277-1282
16. Menezes Oliveira JL, Marques-Santos C, Barreto-Filho JA, Ximenes Filho R, de Oliveira Britto AV, Oliveira Souza AH, Prado CM, Pereira Oliveira CR, Pereira RM, Ribeiro Vicente Tde A, Farias CT, Aguiar-Oliveira MH, Salvatori R (2006) Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation. J Clin Endocrinol Metab 91(6): 2093-2099
17. Ozbey N, Telci A, Cakatay U, Yurci A, Molvalilar S (2003) Determination of oxidative protein and lipid damage in adult hypopituitary patients with GH deficiency. J Endocrinol Invest 26(10): 1001-1007
18. Skalicky J, Muzakova V, Kandar R, Meloun M, Rousar T, Palicka V (2008) Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med 46(4): 499-505
19. Rossi R, Dalle-Donne I, Milzani A, Giustarini D (2006) Oxidized forms of glutathione in peripheral blood as biomarkers of oxidative stress. Clin Chem 52(7): 1406-1414
20. Smith JC, Lang D, McEneny J, Evans LM, Scanlon MF, Young I, Davies J (2002) Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency. Clin Endocrinol (Oxf) 56(4): 449-455
21. Scacchi M, Valassi E, Pincelli AI, Fatti LM, Pecori Giraldi F, Ascoli P, Viarengo R, Cestaro B, Cavagnini F, Cazzola R (2006) Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration. J Endocrinol Invest 29(10): 899-904
22. Sugamura K, Keaney JF Jr (2011) Reactive oxygen species in cardiovascular disease. Free Radic Biol Med. doi: 10.1111/j.1440-1681.2011.05509.x
23. Buus NH, Simonsen U, Pilegaard HK, Mulvany MJ (2000) Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries. Br J Pharmacol 129(1): 184-192